Limmatech Bio News Today : Breaking News, Live Updates & Top Stories | Vimarsana

SCHLIEREN, Switzerland, October 09, 2023--LimmaTech Biologics AG today announced the closing of a USD 37 million (CHF 33 million) Series A financing round co-led by Adjuvant Capital, AXA IM Alts, and the Novo Holdings REPAIR Impact Fund. The proceeds will enable LimmaTech to advance its proprietary technology platform and accelerate its pipeline of preclinical and clinical vaccine candidates against increasingly dangerous bacterial infections, including programs addressing shigellosis and gonorr

SCHLIEREN, Switzerland--(BUSINESS WIRE)--LimmaTech Biologics AG today announced the closing of a USD 37 million (CHF 33 million) Series A financing round co-led by Adjuvant Capital, AXA IM Alts, and the Novo Holdings REPAIR Impact Fund. The proceeds will enable LimmaTech to advance its proprietary technology platfor...

LimmaTech has leveraged a novel technology platform to produce a pipeline of vaccines against multi-resistant bacterial infections that present global health threatsSCHLIEREN, Switzerland--(BUSINESS WIRE)--LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threate...